Full Press Release Details
1 Corporate Presentation
2 Legal Disclaimer This
presentation of Pelthos Therapeutics Inc. ("we", "us", "our" or the "Company")
contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other
securities laws. Words such as "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict, "project,"
"seek," "should," "target," "will," "would" or similar expressions
and the negatives of those term are intended to identify forward-looking statements. Forward-looking statements reflect management's
current expectations, are based on judgments and assumptions, are inherently uncertain and are subject to risks, uncertainties
and other factors, which could cause the Company's actual results, performance or achievements to differ materially from
expected future results, performance or achievements expressed or implied in those forward-looking statements. Examples of these
forward-looking statements and the related risks, uncertainties and other factors include, but are not limited to, the following:
the success of the launch for Zelsuvmi, timing, progress and results of any preclinical and clinical trials, its estimates regarding
the potential market opportunity for Zelsuvmi, its ability to develop its pipeline, its ability to protect its intellectual property
and enforce its intellectual property rights, and its ability to execute its development strategy and sustain its competitive
position. Actual future results and trends may differ materially depending on a variety of factors, including, but not limited
to, the Company's limited operating history, the Company's ability to establish its market development capabilities
to commercialize its products and generate any revenue, and the Company's ability to maintain regulatory approval of Zelsuvmi.
Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs
and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Any forward-looking
statement in this presentation, in any related presentation supplement and in any related free writing presentation reflects our
current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to
our business, results of operations, industry and future growth. You should read this presentation with the understanding that
our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.
Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if
new information becomes available in the future.
3 3 - Large addressable
market with $2,008.50 wholesale acquisition cost ("WAC") - Launched July 2025 - Modest acquisition cost,
unencumbered future revenue stream - Expected launch in late 2026 - 6-12 million U.S. cases annually - Expected
launch during the first half of 2027 Investment Highlight ? Commercial biopharmaceutical company focused on growing, differentiated
cutaneous infections product portfolio ? Highly synergistic Xepi and Xeglyze product acquisitions leverage Zelsuvmi's current
commercial and market access team and infrastructure ? Strong potential revenue streams with very attractive gross to nets ? Disciplined,
accretive, cost-efficient product acquisition model and experienced management team to manage execution Product Portfolio
Key Data Points (as of 01/09/26, except where noted) Ticker PTHS Stock Price $25.93 O/S Shares of Common Stock (on an as converted
basis) 8.9M Market CAP ~$230M Avg. Daily Trading Volume 21,600 shares (NYSE) Cash at close of Q3 $14.2M (Company issued $18M convertible
note in November Investment to date >$400M Pelthos is a competitive drug portfolio company - committed to commercializing
innovative, safe, and efficacious therapeutic products to help patients with unmet dermatological treatment burdens Zelsuvmi:
Launched in July 2025. - First and only at home treatment addressing Molluscum contagiosum ("MC"), a large, underserved
market treating contagious viral disease Recent portfolio acquisitions: Two FDA-approved complimentary dermatological acquisitions,
will leverage Zelsuvmi commercial infrastructure buildout - Xepi (ozenoxacin) Cream 1% - novel topical treatment for impetigo
- First line impetigo treatment addresses antimicrobial resistance in pediatric dermatology, drug relaunch expected in late
2026 - Xeglyze (abametapir) Lotion 0.74% - novel topical treatment for head lice - Commercial launch expected in 2027
Experienced management team: Over 20 successful prior drug launches, including Cosentyx, Otezla, Ohtuvayre, Xifaxan Current peak
Net Revenue forecast of $175M per annum based on Zelsuvmi alone by 2028
5 Management Team Frank
Knuettel | Chief Financial Officer Sai Rangarao | Chief Commercial Officer Scott Plesha | Chief Executive Officer - 30 years
of management experience in growing early-stage companies - Raised more than $400 million viaventure, public equity and debt
offerings and managed more than 15 mergersand acquisition transactions along with large-scale licensing transactions with fortune
50companies - Holds numerous board positions, at both public andprivate companies, including Etheros Pharmaceuticals -
Earned an MBA from The Wharton School and a BA from Tufts University - >30 years of experience in the pharmaceutical industry,
including two decades building andleading specialty pharma commercial efforts - President and Chief Commercial Officer at
BDSI until it was acquired by Collegium Pharmaceutical in 2022 - Grew BDSI sales from $5 million to $160 million - Previously
served as Senior Vice President of Gastrointestinal Sales at SalixPharmaceuticals. During fifteen-year tenure at Salix, led nationwide
salesforce that grew product sales to more than $1.5 billion annually - Earned a BA inPre-Medicine and Pre-Medical Studies
at DePauw University and pursued graduatestudies in Dentistry at Indiana University Dental School - >18 years of experience
leading, launching, and marketing pharmaceutical products - VP of Marketing & Head of Neurology Sales at Collegium Pharmaceutical
- VP of Marketing & Commercial Operations at BDSI, until it was acquired by Collegium in 2022 - Head of US Dermatology
Marketing for Otezla at Celgene leading to acquisition by Amgen for $13 Billion - Member of the commercial and marketing
organization at Novartis Pharmaceuticals that launched COSENTYX in the U.S - Earned an MS in Bioscience Regulatory Affairs
from The Johns Hopkins University, an MBA and MS from the New Jersey Institute of Technology, and a BS in Computer Science from
Indiana University of Pennsylvania
6 Board of Directors
Peter Greenleaf, Chairman Richard Baxter Ezra Friedberg Todd Davis Richard Malamut , MD Matt Pauls Scott Plesha Andrew Einhorn
molluscum & Zelsuvmi
8 Molluscum Contagiosum
A highly infectious viral condition primarily affecting children 1 year of age or older There are four known types of MC virus
(MCV1, 2, 3, 4) with MCV1 being the most common1 Molluscum Contagiosum is caused by a pox virus and is characterized by small,
round, firm, umbilicated, often painless bumps. Even after healing, re-infection is possible if in contact with an infected person
or object4. ~17 million people infected in the U.S. MC can take up to five years to resolve without treatment2 Peak incidence
between 1-10 years of age. Up to 73% of children go untreated3 Point prevalence of 3-6 million children (ages 0-16) in the U.S.
Infection, Persistence, and Spread Visible and Psychological Impacts Pain & Skin Irritation Auto- inoculation2 Highly contagious
to others ? risk of secondary bacterial infections2 Potential worsening of atopic dermatitis Itching, redness Inflammation Anxiety
Social withdrawal Untreated Molluscum Contagiosum Has Severe Effects 1) Hebert AA, Bhatia N, Del Rosso JQ. Molluscum Contagiosum:
Epidemiology, Considerations, Treatment Options, and Therapeutic Gaps. J Clin Aesthet Dermatol. 2023 Aug;16(8 Suppl 2):S4-S11.
PMID: 37636018; PMCID: PMC10453394. 2.)Ludmann P. American Academy of Dermatology. Molluscum contagiosum. 4 October 2023. 3) Basdag
H, Rainer BM, Cohen BA. Molluscum contagiosum: to treat or not to treat? Experience with 170 children in an outpatient clinic
setting in the northeastern United States. Pediatr Dermatol. 2015;32(3):353-357. doi:10.1111/pde.12504. 4) Schaffer JV, Berger
EM. Molluscum Contagiosum. JAMA Dermatol. 2016;152(9):1072. doi:10.1001/jamadermatol.2016.2367. 5) CDC. Clinical Overview of Molluscum
Contagiosum. Jan 2025
9 Zelsuvmi Has the Potential
to Shift MC Treatment Paradigm Previous Treatment Options - Painful, destructive treatments3 - Attractive safety profile
demonstrated in clinical trials with no / minimal scarring5,6 - Remaining treatment options such as off-label drugs / natural
remedies have unproven efficacy4 - Demonstrated, proven efficacy across key primary and secondary endpoints in clinical trials6
- Necessitates travel to HCP offices, adding to the time burden for MC patients and caregivers2 - First FDA approved
medication for molluscum that can be applied at home by patients or caregivers5 - Other available topical treatment requires
in-office visits every 3 weeks2 - Daily application that can be started immediately 1.)Least-squares mean count reduction.
See Figure 9: Browning JC, Hebert A, Enloe C, Cartwright M, Maeda-Chubachi T. Berdazimer Gel 10.3% is a Clinically Meaningful
Therapeutic Intervention for Molluscum Contagiosum. Abstract and poster presented at Fal l Cl inical 2024. Las Vegas, NV. October
24-27, 2024. 2.) Eichenfield LF, Kwong P, Gonzalez ME, et al. Safety and Efficacy of VP-102 (Cantharidin, 0.7% w/v) in Molluscum
Contagiosum by Body Region: Post hoc Pooled Analyses from Two Phase III Randomized Trials. J Clin Aesthet Dermatol. 2021;14(10):42-47.
3.) Hebert AA, Bhatia N, Del Rosso JQ. Molluscum Contagiosum: Epidemiology, Considerations, Treatment Options, and Therapeutic
Gaps. J Cl in Aesthet Dermatol. 2023;16(8 Suppl 1):S4-S11. 4.) Ong SK, Hoft I, Siegfried E. Analysis of over-the-counter products
marketed to treat molluscum contagiosum. Pediatr Dermatol . 2021;38(5):1400-1403. doi:10.1111/pde.14776. 5.) Zelsuvmi Package
Insert. 6.) Sugarman JL, Hebert A, Browning JC, et al. Berdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized
controlled trials. J Am Acad Dermatol. 2024;90(2):299-308. doi:10.1016/j.jaad.2023.09.066Ong The 1st & Only At Home Prescription
10 Intervention Population
Key Study Highlights B-SIMPLE4 Primary Outcome B-SIMPLE4 Study Locations 1) p-value <0.0001, favoring Zelsuvmi .. Source: Sugarman
JL, Hebert A, Browning JC, Paller AS, Stripling S, Green LJ, Cartwright M, Enloe C, Wells N, Maeda-Chubachi T. Berdazimer gel
for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials. J Am Acad Dermatol. 2023 Oct 5:S0190-9622(23)02890-6.